AbbVie Presents New Upadacitinib Data In Atopic Dermatitis

AbbVie Inc ABBV announced new analyses from the Phase 3 Rinvoq (upadacitinib) atopic dermatitis clinical trial program.
Data were presented at the European Academy of Dermatology and Venereology (EADV) Virtual Congress.
One analysis showed a greater proportion of patients treated with Rinvoq (15 mg or 30 mg; once daily) with or without topical corticosteroids achieved 75% improvement in the Eczema Area Severity Index (EASI 75) at week 16 compared to placebo regardless of age, sex, race, weight, disease severity and previous exposure to systemic therapy.
An additional analysis showed that more patients treated with Rinvoq 30 mg achieved EASI 75 at week 16 than dupilumab when measured in four body regions.
No new safety risks were observed.
Price Action: ABBV stock is down 0.03% at $108.81 during the market session on the last check Thursday.
Editor's Note: The story has been updated with additional details.